These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3447909)

  • 41. Ulcerogenicity of piroxicam: an analysis of spontaneously reported data.
    Rossi AC; Hsu JP; Faich GA
    Br Med J (Clin Res Ed); 1987 Jan; 294(6565):147-50. PubMed ID: 3109543
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury.
    Lichtenberger LM; Wang ZM; Romero JJ; Ulloa C; Perez JC; Giraud MN; Barreto JC
    Nat Med; 1995 Feb; 1(2):154-8. PubMed ID: 7585013
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characteristics of ulcers of the small bowel induced by non-steroidal anti-inflammatory drugs in the rat: implications for clinical practice.
    Collins AJ; Reid J; Soper CJ; Notarianni LJ
    Br J Rheumatol; 1995 Aug; 34(8):727-31. PubMed ID: 7551656
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Models of inflammation: measuring gastrointestinal ulceration in the rat.
    Whiteley PE; Dalrymple SA
    Curr Protoc Pharmacol; 2001 May; Chapter 10():Unit 10.2. PubMed ID: 21971793
    [No Abstract]   [Full Text] [Related]  

  • 45. Enteroscopic diagnosis of small bowel ulceration in patients receiving non-steroidal anti-inflammatory drugs.
    Morris AJ; Madhok R; Sturrock RD; Capell HA; MacKenzie JF
    Lancet; 1991 Mar; 337(8740):520. PubMed ID: 1671893
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of copper in preventing gastrointestinal damage by acidic anti-inflammatory drugs.
    Boyle E; Freeman PC; Goudie AC; Mangan FR; Thomson M
    J Pharm Pharmacol; 1976 Dec; 28(12):865-8. PubMed ID: 12259
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Further investigations of indomethacin and intestinal ulcers in the rat.
    Del Soldato P; Meli A
    Toxicology; 1978 Feb; 9(1-2):69-74. PubMed ID: 653743
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Further studies on the mechanism of fat-free diet (FFD)--protection against indomethacin-induced intestinal ulcers in the rat.
    Evangelista S; Ciappi R; Ortolani C; Barzanti A; Meli A
    Proc Soc Exp Biol Med; 1985 May; 179(1):113-5. PubMed ID: 3991592
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diclofenac acyl glucuronide, a major biliary metabolite, is directly involved in small intestinal injury in rats.
    Seitz S; Boelsterli UA
    Gastroenterology; 1998 Dec; 115(6):1476-82. PubMed ID: 9834275
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biliary elimination of non-steroidal anti-inflammatory drugs in patients.
    Schneider HT; Nuernberg B; Dietzel K; Brune K
    Br J Clin Pharmacol; 1990 Jan; 29(1):127-31. PubMed ID: 2297457
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Resistance of germfree rats to indomethacin-induced intestinal lesions.
    Robert A; Asano T
    Prostaglandins; 1977 Aug; 14(2):333-41. PubMed ID: 331401
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pathogenesis of diclofenac enteropathy.
    Somasundaram S
    Gastroenterology; 2001 Jun; 120(7):1885; author reply 1886-7. PubMed ID: 11398796
    [No Abstract]   [Full Text] [Related]  

  • 53. [A comparative study in the rat of two routes of administration of 14 c-labeled sodium m-trifluoromethyl-1, 3-diphenyl-4-hydroxymethylene-5-pyrazolone].
    Viala A; Paulin R; Cano JP; Durand A; Placidi M; Roux F; Lefournier C
    Therapie; 1976; 31(4):541-55. PubMed ID: 1087475
    [No Abstract]   [Full Text] [Related]  

  • 54. Why the mesenteric margin?
    Anthony A
    Gastroenterology; 2001 Jun; 120(7):1885-6; author reply 1886-7. PubMed ID: 11398795
    [No Abstract]   [Full Text] [Related]  

  • 55. Ileo-caecal ulceration associated with the use of diclofenac slow release.
    Hudson N; Wilkinson MJ; Swannell AJ; Steele RJ; Hawkey CJ
    Aliment Pharmacol Ther; 1993 Apr; 7(2):197-200. PubMed ID: 8485273
    [TBL] [Abstract][Full Text] [Related]  

  • 56. On the relationship between ulcerogenic and anti-inflammatory properties of indomethacin.
    Evangelista S; Meli A
    J Pharm Pharmacol; 1983 Apr; 35(4):250-1. PubMed ID: 6133937
    [No Abstract]   [Full Text] [Related]  

  • 57. Jejunal ulcers produced by indomethacin.
    Somogyi A; Kovács K; Selye H
    J Pharm Pharmacol; 1969 Feb; 21(2):122-3. PubMed ID: 4388092
    [No Abstract]   [Full Text] [Related]  

  • 58. An intestinal disease produced experimentally by a prostaglandin deficiency.
    Robert A
    Gastroenterology; 1975 Oct; 69(4):1045-7. PubMed ID: 1175882
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Indomethacin-induced intestinal ulcers in rats: effects of salicylazosulfapyridine and dexamethasone.
    Del Soldato P; Foschi D; Varin L; Daniotti S
    Agents Actions; 1985 Jul; 16(5):393-6. PubMed ID: 2864817
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Etiological mechanism of drug-induced intestinal diseases].
    Yoshida Y; Murata Y
    Nihon Naika Gakkai Zasshi; 1995 Feb; 84(2):241-8. PubMed ID: 7722390
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.